Skip to content
Aminoscope
Head-to-head

CagriSema vs Semaglutide

CagriSema is semaglutide with an amylin analog added in the same weekly shot; the question is whether the second pathway earns its place, and it is not approved.

By Julian RothResearch & dataUpdated October 2026

Short answer

On weight loss, CagriSema comes out ahead, with 20.4% at 68 weeks in REDEFINE 1 against 14.9% at 68 weeks in STEP 1 for semaglutide. Those figures come from separate trials, not a head-to-head study. Only semaglutide is FDA-approved; CagriSema is still investigational in the US. Semaglutide is a prescription drug, while CagriSema is legitimately available only inside clinical trials.

CagriSema

Clinical data

~20% in REDEFINE 1; amylin plus GLP-1 in one shot — promising, not yet approved.

Full CagriSema evidence review

Semaglutide

Wegovy / Ozempic

FDA-approved

~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.

Full Semaglutide evidence review

CagriSema vs Semaglutide: head to head

FDA status / approved use

CagriSema

Investigational; Phase 3 REDEFINE trials completed, regulatory status still pending

Semaglutide

FDA-approved
Marketed for

CagriSema

Weight loss

Semaglutide

Weight loss, type-2 diabetes
Outcome areas

CagriSema

Weight loss / appetite

Semaglutide

Weight loss / appetite; Blood sugar / insulin sensitivity
Evidence grade

CagriSema

Clinical data

Semaglutide

FDA-approved
How it works

CagriSema

Pairs an amylin analog with a GLP-1 agonist to curb appetite two ways

Semaglutide

GLP-1 receptor agonist
Route and dosing

CagriSema

Injection, once weekly

Semaglutide

Subcutaneous, once weekly (Wegovy label); maintenance 2.4 mg (recommended) or 1.7 mg once weekly
Headline human result

CagriSema

20.4% mean weight loss vs 3% on placebo at 68 weeks (REDEFINE 1, 2.4 mg + 2.4 mg weekly)

Semaglutide

14.9% mean weight loss vs 2.4% on placebo at 68 weeks (STEP 1, 2.4 mg weekly)
Strongest evidence

CagriSema

REDEFINE 1, NEJM 2025CagriSema evidence reviewPubMed 40544433

Semaglutide

STEP 1, NEJM 2021Semaglutide evidence reviewPubMed 33567185
Key safety signal

CagriSema

GI side effects common; no long-term cardiovascular-outcomes evidence yet

Semaglutide

Nausea, vomiting and constipation, mainly when the dose is raised too quickly
How it is obtained

CagriSema

Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals

Semaglutide

Prescription. Manufacturer self-pay for Wegovy (injection pen) runs $349–$399 per fill, against a $1,349 list priceWegovy cost breakdown

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

FDA-approved:
Approved by the FDA for a defined indication, on the strength of pivotal human trials.
Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Semaglutide is approved and has the deeper record: about 14.9% mean weight loss in STEP 1, the STEP 4 data showing substantial regain after stopping, and a roughly 20% reduction in major adverse cardiovascular events in SELECT. CagriSema reported about 20% in REDEFINE 1 and also beat placebo in REDEFINE 2, but it is investigational, has no long-term cardiovascular outcomes evidence, and its topline landed below pre-trial expectations, partly because many participants did not reach the highest target dose. REDEFINE 1 did randomize against the individual components as well as placebo, which makes it the closest thing to a direct read in this pair.

CagriSema fits if

You are watching whether pairing amylin with GLP-1 becomes an approved option, and you read Phase 3 data before it reaches the clinic.

Semaglutide fits if

You want a GLP-1 that can actually be prescribed, with hard cardiovascular outcome evidence behind it.

CagriSema vs Semaglutide: common questions

Is semaglutide FDA-approved but CagriSema not?
Yes. Semaglutide is FDA-approved. CagriSema is investigational; Phase 3 REDEFINE trials completed, regulatory status still pending.
Which has stronger human evidence, CagriSema or semaglutide?
Semaglutide. It has approval-level evidence (key source: STEP 1, NEJM 2021), while CagriSema has human clinical data (key source: REDEFINE 1, NEJM 2025).
What are the main safety concerns with CagriSema and semaglutide?
For CagriSema, watch for common GI side effects; no long-term cardiovascular-outcomes evidence yet. For semaglutide, watch for nausea, vomiting and constipation, mainly when the dose is raised too quickly.

Key studies behind each

CagriSema

  1. Lau DCW, Erichsen L, Francisco AM, et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. PubMed 34798060
  2. Enebo LB, Berthelsen KK, Kankam M, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. PubMed 33894838
  3. Garvey WT, Blüher M, Osorto Contreras CK, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. PubMed 40544433
  4. Verma S, et al. (2026). CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. PubMed 41328546

Semaglutide

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PubMed 33567185
  2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. PubMed 33755728
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PubMed 37952131
  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PubMed 35658024

The full evidence reviews

Related comparisons